Mela shares drop on FDA review; Breathe gets new CEO

> Shares of medical device maker Mela Sciences were off sharply in midday trading, on news that the FDA has released documents indicating that the company's melanoma detection device might be harmful due to the risk of mis-diagnosis. Story

> Breathe Technologies, manufacturer of devices for respiratory insufficiency, announced the board of directors has appointed Lawrence Mastrovich as the new president and CEO. Breathe release

> VisionCare Ophthalmic Technologies, a developer of advanced visual prosthetic devices, today announced the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), designed to improve vision in patients with end-stage age-related macular degeneration (AMD) is named "Best of What's New" 2010 by Popular Science magazine. VisionCare release

> Genzyme CEO Henri Termeer has cut his stake in Danvers, Massachusetts-based Abiomed by about 5.4 percent over the past year. Story

> Higher doses of the blood-thinner Plavix were no better at preventing heart attacks, blood clots or death than the standard lower dose in patients who had received artery-opening stents, new research shows. Article

> The Miller group of companies is excited to announce that it has successfully integrated its acquisition of Creative Technology Services and formed a new division, Miller Technical Services (MTS).  Located in Canton, MI, MTS specializes in contract manufacturing and assembly of complex medical devices. It is one of the only Class III, radiation-certified, independent contract manufacturers in the U.S. The company's current focus is on electro-mechanical devices where it has extensive experience in design, engineering, manufacturing, assembly, testing, refurbishing, depot and field service. MTS release

> Menicon has announced its agreement with Optimed to become the exclusive distributor for Optimed's CAPTIV8 communication services and i-Vue content-driven digital signage software for North America. Earlier this year, Menicon obtained exclusive distribution rights for Optimed's products in Japan and Taiwan. Menicon release

And Finally... Researchers have developed an artificial retina that has the capacity to reproduce normal vision in mice. While other prosthetic strategies mainly increase the number of electrodes in an eye to capture more information, this study concentrated on incorporating the eye's neural "code" that converts pictures into signals the brain can understand. Story

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.